)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Eoflow
Eoflow (294090) investor relations material
Eoflow Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary14 Aug, 2026
Executive summary
Specializes in wearable medical devices, focusing on insulin patch pumps and automated insulin delivery systems for diabetes management.
Faced significant operational and financial challenges due to ongoing litigation with Insulet Corporation, impacting sales and market access.
Major shareholder changed to Citadel Multi-Asset Master Fund Ltd. after a third-party allotment in late 2025.
Financial highlights
1H 2026 consolidated revenue was KRW 222 million, down sharply from KRW 1,897 million in 1H 2025.
Operating loss for 1H 2026 was KRW -5,760 million; net loss was KRW -14,037 million.
Total assets at June 30, 2026: KRW 31,011 million; total liabilities: KRW 78,320 million; negative equity of KRW -47,309 million.
Cash and cash equivalents at period end: KRW 3,051 million.
No dividends paid due to accumulated losses.
Outlook and guidance
Plans to resume global sales and expand user base as litigation-related uncertainties are resolved.
Focus on FDA approval and North American market entry, with ongoing product development and regulatory preparations.
Strategic emphasis on partnerships and diversified funding to reduce reliance on a single investor.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Eoflow
- Severe losses and legal setbacks threaten liquidity and market access amid ongoing restructuring.294090
Q2 2025 - Severe losses, negative equity, and litigation threaten liquidity and business continuity.294090Q3 2025
- Litigation-induced sales collapse led to steep losses, negative equity, and severe liquidity risk.294090Q1 2026
- 2024 saw deepening losses, severe liquidity issues, and major legal setbacks, raising survival concerns.294090Q4 2024
- Litigation drove a 30% revenue drop, deep losses, and a change in largest shareholder.294090Q4 2025
Next Eoflow earnings date
Q3 202620 Nov, 2026
Eoflow
Next Eoflow earnings date
Q3 202620 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Eoflow Co., Ltd. is a South Korean medical device company specializing in the development and production of wearable drug delivery systems, with a focus on insulin delivery for diabetes management. The company’s primary product is a compact, wearable insulin pump designed to provide continuous and precise insulin administration, supporting the needs of individuals with diabetes. Eoflow leverages advanced microfluidic and electrochemical technology to enhance device functionality and user convenience. The company is headquartered in Seongnam, South Korea, and its shares are listed on the KOSDAQ.